Cellectis Presents at the ESGCT Annual Congress
Excitement is building as Cellectis, a pioneering clinical-stage biotechnology company focused on innovative gene-editing, prepares to showcase their latest research. At the European Society of Cell and Gene Therapy (ESGCT) 31st Annual Congress, Cellectis will present pre-clinical data that promises advancements in TALE base editors and non-viral gene therapy methodologies.
Innovative Approaches in Gene Editing
The company emphasizes its commitment to developing life-saving therapies by exploring the potential of TALE base editors (TALEB). These sophisticated tools allow for precise editing of genes, offering new avenues for treating genetic disorders and enhancing cell therapies.
Key Presentations
During the congress, two significant posters will be highlighted. The first, titled "Controlling C-to-T editing with TALE base editors," will be presented by Alexandre Juillerat, Ph.D., who serves as the Vice-President of Gene Editing and Head of the New York Lab at Cellectis. This presentation aims to disclose insights into how C-to-T conversions can be optimally controlled and their implications for gene editing.
Research on Gene Insertion Techniques
The second poster, presented by Julien Valton, Ph.D., the Vice-President of Gene Therapy at the company, focuses on the findings surrounding circular single-stranded DNA (CssDNA). The research indicates that CssDNA significantly increases gene insertion rates in hematopoietic stem and progenitor cells (HSPCs), marking a step forward for non-viral gene therapy.
Enhancing the Efficacy of Non-Viral Gene Therapy
The essence of the research centers on improving how genes are inserted into cells without the use of viral vectors, which has been a common constraint in gene therapy practices. Employing advanced TALEN® technology, Cellectis has shown how non-viral donors, particularly CssDNA, can lead to higher efficacy in gene insertion, addressing one of the major hurdles in current therapies.
The Outcome and Future Directions
The results of Cellectis' studies aim not only to showcase the power of TALEB but also to outline the vast potential that lies ahead in gene editing. The advancements presented at this congress could redefine therapeutic strategies and greatly enhance the treatment landscape for various genetic disorders.
About Cellectis
Cellectis, headquartered in Paris, France, with locations in New York and Raleigh, North Carolina, is recognized for its prolific work in the gene-editing space. With an experience spanning over 25 years, the company utilizes its TALEN® technology to develop revolutionary therapies for oncology and other severe conditions.
Expertise in Gene Therapy
The commitment of Cellectis to creating off-the-shelf, ready-to-use CAR-T therapies highlights its innovative stance in the biotechnology industry. This approach not only offers patients timely treatment options but also opens new doors for targeted therapies.
Follow Our Journey
To learn more about the exciting developments at Cellectis, visit www.cellectis.com. Engage with us on social media to stay updated on our latest research and breakthroughs.
Frequently Asked Questions
What is Cellectis known for?
Cellectis is renowned for its innovative gene-editing techniques and development of gene therapies aimed at treating various diseases.
What technologies does Cellectis use?
The company primarily utilizes TALEN® technology for gene editing and PulseAgile for electroporation to improve therapeutic applications.
Where will Cellectis present its research?
Cellectis will showcase its findings at the European Society of Cell and Gene Therapy's 31st Annual Congress.
Who are the presenters at the congress?
Alexandre Juillerat and Julien Valton will present key findings related to TALE base editors and non-viral gene therapy.
How does CssDNA enhance gene therapy?
The use of circular single-stranded DNA significantly improves gene insertion rates, which can lead to more effective therapies in preclinical models.
